Middle East & Africa Infectious Disease Therapeutics Market Forecast to 2030 - Regional Analysis - by Drug Class (Anti-viral, Anti-Bacterial, Anti-Fungal, and Others), Indication (HIV, Hepatitis, Tuberculosis, Influenza, HPV, and Others), Route of Administration (Oral, Parenteral, Topical, and Others), and Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Others)
The Middle East & Africa infectious disease therapeutics market was valued at US$ 5,722.81 million in 2022 and is expected to reach US$ 7,237.61 million by 2030; it is estimated to register a CAGR of 3.0% from 2022 to 2030.
Rising Prevalence of Infectious Disease Fuels Middle East & Africa Infectious Disease Therapeutics Market
Infectious diseases are caused by viruses, parasites, bacteria, fungi, toxic products, and other infectious agents. HIV is a major public health issue across the world. According to The Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2020, ~ 37.7 million people had HIV. Out of these, 36 million were adults, and 1.7 million were children aged 0-14 years. Also, more than half (53%) were girls and women. Moreover, 1.5 million new HIV cases were reported in 2020 globally. Similarly, hepatitis is an infection of the liver caused by a viral infection. The main types of hepatitis viruses are A, B, C, D, and E. According to the World Health Organization (WHO), globally, ~ 58 million people are suffering from chronic hepatitis C virus infection, and every year, ~1.5 million new infections occur.
According to WHO, tuberculosis (TB) is the 13th top cause of death globally and the second leading infectious disease after COVID-19. In 2020, 1.5 million deaths were caused by TB (including 214,000 people affected by HIV). Furthermore, 10 million people had TB globally in 2020, including 1.1 million children, 3.3 million women, and 5.6 million men. Moreover, hospital-acquired infections or healthcare-associated infections (HAIs) have a high morbidity and mortality rate. Also, the expenditure on the healthcare system is huge every year. Therefore, the rising prevalence of infectious diseases across the globe drives the growth of the infectious disease therapeutics market.
Middle East & Africa Infectious Disease Therapeutics Market Overview
The infectious disease therapeutics market in the Middle East & Africa includes a country-level analysis of the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. The market growth can be attributed to the increasing prevalence of chronic viral diseases and growing research studies across the region. Moreover, the emergence of advanced healthcare facilities is likely to propel market growth during the forecast period. Saudi Arabia is among the fastest-growing regions in the Middle East & Africa, driven by a huge population base and the increasing prevalence of infectious diseases. Tuberculosis in Saudi Arabia is spread through migrant workers and pilgrims. According to the World Data Atlas, the incidence rate of tuberculosis in Saudi Arabia gradually fell from 17 cases per 100,000 people in 2002 to 8 cases per 100,000 people in 2021. Further, K. pneumoniae, a hospital-acquired infection of the urinary tract, bloodstream, and respiratory tract, is very challenging to control in Saudi Arabia. Influenza and pneumonia deaths reached 4.58% of total deaths in the country, according to WHO. To address the growing influenza cases, the Public Health Laboratory in Saudi Arabia fulfilled all the requirements by WHO to be recognized as a national influenza center for Saudi Arabia. The center plays a critical role in rapidly detecting and monitoring infectious diseases. NIAID is significantly involved in research on infectious viral diseases in the region, including MERS-CoV. MERS-CoV, a newly identified coronavirus, has spread to at least nine countries in the region. NIAID is significantly involved in research on infectious viral diseases in the region. Similarly, product launches in the region are increasing and are positively impacting patients' quality of life. Thus, the growing number of viral diseases and product launches is anticipated to propel the growth of infectious disease therapeutics in the country.
Middle East & Africa Infectious Disease Therapeutics Market Revenue and Forecast to 2030 (US$ Million)
Middle East & Africa Infectious Disease Therapeutics Market Segmentation
The Middle East & Africa infectious disease therapeutics market is categorized into drug class, indication, route of administration, distribution channel, and country.
Based on drug class, the Middle East & Africa infectious disease therapeutics market is segmented into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022.
In terms of indication, the Middle East & Africa infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV held the largest market share in 2022.
Based on route of administration, the Middle East & Africa infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held the largest market share in 2022.
In terms of distribution channel, the Middle East & Africa infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies held the largest market share in 2022.
By country, the Middle East & Africa infectious disease therapeutics market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa infectious disease therapeutics market share in 2022.
AbbVie Inc, Astellas Pharma Inc, Bayer AG, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc , Merck & Co Inc, and Pfizer Inc are some of the leading companies operating in the Middle East & Africa infectious disease therapeutics market.
Rising Prevalence of Infectious Disease Fuels Middle East & Africa Infectious Disease Therapeutics Market
Infectious diseases are caused by viruses, parasites, bacteria, fungi, toxic products, and other infectious agents. HIV is a major public health issue across the world. According to The Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2020, ~ 37.7 million people had HIV. Out of these, 36 million were adults, and 1.7 million were children aged 0-14 years. Also, more than half (53%) were girls and women. Moreover, 1.5 million new HIV cases were reported in 2020 globally. Similarly, hepatitis is an infection of the liver caused by a viral infection. The main types of hepatitis viruses are A, B, C, D, and E. According to the World Health Organization (WHO), globally, ~ 58 million people are suffering from chronic hepatitis C virus infection, and every year, ~1.5 million new infections occur.
According to WHO, tuberculosis (TB) is the 13th top cause of death globally and the second leading infectious disease after COVID-19. In 2020, 1.5 million deaths were caused by TB (including 214,000 people affected by HIV). Furthermore, 10 million people had TB globally in 2020, including 1.1 million children, 3.3 million women, and 5.6 million men. Moreover, hospital-acquired infections or healthcare-associated infections (HAIs) have a high morbidity and mortality rate. Also, the expenditure on the healthcare system is huge every year. Therefore, the rising prevalence of infectious diseases across the globe drives the growth of the infectious disease therapeutics market.
Middle East & Africa Infectious Disease Therapeutics Market Overview
The infectious disease therapeutics market in the Middle East & Africa includes a country-level analysis of the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa. The market growth can be attributed to the increasing prevalence of chronic viral diseases and growing research studies across the region. Moreover, the emergence of advanced healthcare facilities is likely to propel market growth during the forecast period. Saudi Arabia is among the fastest-growing regions in the Middle East & Africa, driven by a huge population base and the increasing prevalence of infectious diseases. Tuberculosis in Saudi Arabia is spread through migrant workers and pilgrims. According to the World Data Atlas, the incidence rate of tuberculosis in Saudi Arabia gradually fell from 17 cases per 100,000 people in 2002 to 8 cases per 100,000 people in 2021. Further, K. pneumoniae, a hospital-acquired infection of the urinary tract, bloodstream, and respiratory tract, is very challenging to control in Saudi Arabia. Influenza and pneumonia deaths reached 4.58% of total deaths in the country, according to WHO. To address the growing influenza cases, the Public Health Laboratory in Saudi Arabia fulfilled all the requirements by WHO to be recognized as a national influenza center for Saudi Arabia. The center plays a critical role in rapidly detecting and monitoring infectious diseases. NIAID is significantly involved in research on infectious viral diseases in the region, including MERS-CoV. MERS-CoV, a newly identified coronavirus, has spread to at least nine countries in the region. NIAID is significantly involved in research on infectious viral diseases in the region. Similarly, product launches in the region are increasing and are positively impacting patients' quality of life. Thus, the growing number of viral diseases and product launches is anticipated to propel the growth of infectious disease therapeutics in the country.
Middle East & Africa Infectious Disease Therapeutics Market Revenue and Forecast to 2030 (US$ Million)
Middle East & Africa Infectious Disease Therapeutics Market Segmentation
The Middle East & Africa infectious disease therapeutics market is categorized into drug class, indication, route of administration, distribution channel, and country.
Based on drug class, the Middle East & Africa infectious disease therapeutics market is segmented into anti-viral, anti-bacterial, anti-fungal, and others. The anti-viral segment held the largest market share in 2022.
In terms of indication, the Middle East & Africa infectious disease therapeutics market is segmented into HIV, hepatitis, tuberculosis, influenza, HPV, and others. The HIV held the largest market share in 2022.
Based on route of administration, the Middle East & Africa infectious disease therapeutics market is segmented into oral, parenteral, topical, and others. The oral segment held the largest market share in 2022.
In terms of distribution channel, the Middle East & Africa infectious disease therapeutics market is segmented into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies held the largest market share in 2022.
By country, the Middle East & Africa infectious disease therapeutics market is segmented into Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa. Saudi Arabia dominated the Middle East & Africa infectious disease therapeutics market share in 2022.
AbbVie Inc, Astellas Pharma Inc, Bayer AG, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc, GSK Plc , Merck & Co Inc, and Pfizer Inc are some of the leading companies operating in the Middle East & Africa infectious disease therapeutics market.
1. INTRODUCTION
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET - KEY MARKET DYNAMICS
4.1 Middle East & Africa Infectious Disease Therapeutics Market - Key Market Dynamics
4.2 Market Drivers
4.2.1 Rising Prevalence of Infectious Disease
4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics
4.3 Market Restraints
4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects
4.4 Market Opportunities
4.4.1 Escalating Threat of Antibiotic Resistance
4.5 Future Trends
4.5.1 Rising Number of Product Approvals and Launches
4.6 Impact of Drivers and Restraints:
5. INFECTIOUS DISEASE THERAPEUTICS MARKET - MIDDLE EAST & AFRICA MARKET ANALYSIS
5.1 Middle East & Africa Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
6. MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET ANALYSIS - BY DRUG CLASS
6.1 Overview
6.2 Anti-Viral
6.2.1 Overview
6.2.2 Anti-viral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Anti-bacterial
6.3.1 Overview
6.3.2 Anti-bacterial: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Anti-fungal
6.4.1 Overview
6.4.2 Anti-fungal: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Others
6.5.1 Overview
6.5.2 Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7. MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET ANALYSIS - BY INDICATION
7.1 Overview
7.2 HIV
7.2.1 Overview
7.2.2 HIV: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Hepatitis
7.3.1 Overview
7.3.2 Hepatitis: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Tuberculosis
7.4.1 Overview
7.4.2 Tuberculosis: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Influenza
7.5.1 Overview
7.5.2 Influenza: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.6 HPV
7.6.1 Overview
7.6.2 HPV: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8. MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET ANALYSIS - BY ROUTE OF ADMINISTRATION
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Topical
8.4.1 Overview
8.4.2 Topical: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9. MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET ANALYSIS - BY DISTRIBUTION CHANNEL
9.1 Overview
9.2 Hospital Pharmacies
9.2.1 Overview
9.2.2 Hospital Pharmacies: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Retail Pharmacies
9.3.1 Overview
9.3.2 Retail Pharmacies: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10. MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET - COUNTRY ANALYSIS
10.1 Middle East & Africa Infectious Disease Therapeutics Market
10.1.1 Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
10.1.1.1 Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
10.1.1.2 South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 Overview
10.1.1.3 Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 Saudi Arabia: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.3.2 Saudi Arabia: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.3.3 Saudi Arabia: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.3.4 Saudi Arabia: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.4 South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.1 Overview
10.1.1.5 South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.1 South Africa: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.5.2 South Africa: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.5.3 South Africa: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.5.4 South Africa: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.6 United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.1 Overview
10.1.1.7 United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.7.1 United Arab Emirates: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.7.2 United Arab Emirates: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.7.3 United Arab Emirates: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.7.4 United Arab Emirates: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.8 Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.8.1 Overview
10.1.1.9 Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.9.1 Rest of Middle East & Africa: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.9.2 Rest of Middle East & Africa: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.9.3 Rest of Middle East & Africa: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.9.4 Rest of Middle East & Africa: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
11. INFECTIOUS DISEASE THERAPEUTICS MARKET-INDUSTRY LANDSCAPE
11.1 Overview
11.2 Growth Strategies in the Infectious Disease Therapeutics Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. COMPANY PROFILES
12.1 Pfizer Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Gilead Sciences Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 F. Hoffmann-La Roche Ltd
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Bayer AG
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 GSK Plc
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 AbbVie Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Merck & Co Inc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Astellas Pharma Inc
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
13. APPENDIX
13.1 About The Insight Partners
1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation
2. EXECUTIVE SUMMARY
2.1 Key Insights
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET - KEY MARKET DYNAMICS
4.1 Middle East & Africa Infectious Disease Therapeutics Market - Key Market Dynamics
4.2 Market Drivers
4.2.1 Rising Prevalence of Infectious Disease
4.2.2 Increasing Focus on Funding and R&D in Infectious Disease Therapeutics
4.3 Market Restraints
4.3.1 Emergence of Anti-infective Drugs Resistance and Associated Side Effects
4.4 Market Opportunities
4.4.1 Escalating Threat of Antibiotic Resistance
4.5 Future Trends
4.5.1 Rising Number of Product Approvals and Launches
4.6 Impact of Drivers and Restraints:
5. INFECTIOUS DISEASE THERAPEUTICS MARKET - MIDDLE EAST & AFRICA MARKET ANALYSIS
5.1 Middle East & Africa Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
6. MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET ANALYSIS - BY DRUG CLASS
6.1 Overview
6.2 Anti-Viral
6.2.1 Overview
6.2.2 Anti-viral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Anti-bacterial
6.3.1 Overview
6.3.2 Anti-bacterial: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Anti-fungal
6.4.1 Overview
6.4.2 Anti-fungal: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Others
6.5.1 Overview
6.5.2 Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7. MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET ANALYSIS - BY INDICATION
7.1 Overview
7.2 HIV
7.2.1 Overview
7.2.2 HIV: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Hepatitis
7.3.1 Overview
7.3.2 Hepatitis: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Tuberculosis
7.4.1 Overview
7.4.2 Tuberculosis: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Influenza
7.5.1 Overview
7.5.2 Influenza: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.6 HPV
7.6.1 Overview
7.6.2 HPV: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
7.7 Others
7.7.1 Overview
7.7.2 Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8. MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET ANALYSIS - BY ROUTE OF ADMINISTRATION
8.1 Overview
8.2 Oral
8.2.1 Overview
8.2.2 Oral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Parenteral
8.3.1 Overview
8.3.2 Parenteral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.4 Topical
8.4.1 Overview
8.4.2 Topical: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9. MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET ANALYSIS - BY DISTRIBUTION CHANNEL
9.1 Overview
9.2 Hospital Pharmacies
9.2.1 Overview
9.2.2 Hospital Pharmacies: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.3 Retail Pharmacies
9.3.1 Overview
9.3.2 Retail Pharmacies: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Others
9.4.1 Overview
9.4.2 Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10. MIDDLE EAST & AFRICA INFECTIOUS DISEASE THERAPEUTICS MARKET - COUNTRY ANALYSIS
10.1 Middle East & Africa Infectious Disease Therapeutics Market
10.1.1 Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
10.1.1.1 Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast Analysis - by Country
10.1.1.2 South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.2.1 Overview
10.1.1.3 Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.3.1 Saudi Arabia: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.3.2 Saudi Arabia: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.3.3 Saudi Arabia: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.3.4 Saudi Arabia: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.4 South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.4.1 Overview
10.1.1.5 South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.5.1 South Africa: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.5.2 South Africa: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.5.3 South Africa: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.5.4 South Africa: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.6 United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.6.1 Overview
10.1.1.7 United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.7.1 United Arab Emirates: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.7.2 United Arab Emirates: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.7.3 United Arab Emirates: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.7.4 United Arab Emirates: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
10.1.1.8 Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.8.1 Overview
10.1.1.9 Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
10.1.1.9.1 Rest of Middle East & Africa: Infectious Disease Therapeutics Market Breakdown, by Drug Class
10.1.1.9.2 Rest of Middle East & Africa: Infectious Disease Therapeutics Market Breakdown, by Indication
10.1.1.9.3 Rest of Middle East & Africa: Infectious Disease Therapeutics Market Breakdown, by Route of Administration
10.1.1.9.4 Rest of Middle East & Africa: Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
11. INFECTIOUS DISEASE THERAPEUTICS MARKET-INDUSTRY LANDSCAPE
11.1 Overview
11.2 Growth Strategies in the Infectious Disease Therapeutics Market
11.3 Inorganic Growth Strategies
11.3.1 Overview
11.4 Organic Growth Strategies
11.4.1 Overview
12. COMPANY PROFILES
12.1 Pfizer Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Gilead Sciences Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 F. Hoffmann-La Roche Ltd
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Bayer AG
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 GSK Plc
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 AbbVie Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Merck & Co Inc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Astellas Pharma Inc
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
13. APPENDIX
13.1 About The Insight Partners
LIST OF TABLES
Table 1. Middle East & Africa Infectious Disease Therapeutics Market Segmentation
Table 2. Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Drug Class
Table 3. Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication
Table 4. Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 5. Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 6. Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Country
Table 7. Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 8. Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 9. Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 10. Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 11. South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 12. South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 13. South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 14. South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 15. United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 16. United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 17. United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 18. United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 19. Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 20. Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication
Table 21. Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 22. Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 23. Recent Inorganic Growth Strategies in the Infectious Disease Therapeutics Market
Table 24. Recent Organic Growth Strategies in the Infectious Disease Therapeutics Market12. List of Figures
Figure 1. Middle East & Africa Infectious Disease Therapeutics Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. Middle East & Africa Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
Figure 4. Middle East & Africa Infectious Disease Therapeutics Market Share (%) - by Drug Class (2022 and 2030)
Figure 5. Anti-viral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 6. Anti-bacterial: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Anti-fungal: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Middle East & Africa Infectious Disease Therapeutics Market Share (%) - by Indication (2022 and 2030)
Figure 10. HIV: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hepatitis: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Tuberculosis: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Influenza: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. HPV: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Middle East & Africa Infectious Disease Therapeutics Market Share (%) - by Route Of Administration (2022 and 2030)
Figure 17. Oral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Parenteral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Topical: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Middle East & Africa Infectious Disease Therapeutics Market Share (%) - by Distribution Channel (2022 and 2030)
Figure 22. Hospital Pharmacies: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Retail Pharmacies: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. Middle East & Africa Infectious Disease Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
Figure 26. Middle East & Africa Infectious Disease Therapeutics Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 27. Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 28. South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 29. United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 30. Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 31. Growth Strategies in the Infectious Disease Therapeutics Market
Table 1. Middle East & Africa Infectious Disease Therapeutics Market Segmentation
Table 2. Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Drug Class
Table 3. Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication
Table 4. Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Route of Administration
Table 5. Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Distribution Channel
Table 6. Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Country
Table 7. Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 8. Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 9. Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 10. Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 11. South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 12. South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 13. South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 14. South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 15. United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 16. United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Indication
Table 17. United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 18. United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 19. Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Drug Class
Table 20. Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million) - by Indication
Table 21. Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
Table 22. Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
Table 23. Recent Inorganic Growth Strategies in the Infectious Disease Therapeutics Market
Table 24. Recent Organic Growth Strategies in the Infectious Disease Therapeutics Market12. List of Figures
Figure 1. Middle East & Africa Infectious Disease Therapeutics Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. Middle East & Africa Infectious Disease Therapeutics Market Revenue (US$ Million), 2022-2030
Figure 4. Middle East & Africa Infectious Disease Therapeutics Market Share (%) - by Drug Class (2022 and 2030)
Figure 5. Anti-viral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 6. Anti-bacterial: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Anti-fungal: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Middle East & Africa Infectious Disease Therapeutics Market Share (%) - by Indication (2022 and 2030)
Figure 10. HIV: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hepatitis: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Tuberculosis: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Influenza: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. HPV: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 15. Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. Middle East & Africa Infectious Disease Therapeutics Market Share (%) - by Route Of Administration (2022 and 2030)
Figure 17. Oral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Parenteral: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 19. Topical: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 20. Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 21. Middle East & Africa Infectious Disease Therapeutics Market Share (%) - by Distribution Channel (2022 and 2030)
Figure 22. Hospital Pharmacies: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 23. Retail Pharmacies: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Middle East & Africa Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 25. Middle East & Africa Infectious Disease Therapeutics Market, by Key Country - Revenue (2022) (US$ Million)
Figure 26. Middle East & Africa Infectious Disease Therapeutics Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 27. Saudi Arabia: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 28. South Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 29. United Arab Emirates: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030(US$ Million)
Figure 30. Rest of Middle East & Africa: Infectious Disease Therapeutics Market - Revenue and Forecast to 2030 (US$ Million)
Figure 31. Growth Strategies in the Infectious Disease Therapeutics Market
